efmoroctocog alfa: prescribing and clinical use
Focused clinical detail for use alongside current product information, local policy and patient-specific assessment.
efmoroctocog alfa: clinical details
Prescribing considerations
- Initiate under a clinician experienced in haemophilia management.
- Assess clinical haemostasis and factor VIII recovery because individual response varies.
- Coordinate treatment and laboratory support before surgery, dentistry or invasive procedures.
- Consider cardiovascular risk factors and complications from central venous access devices.
- Record the product name and batch number for biological traceability.
Contraindications and cautions
- Hypersensitivity to efmoroctocog alfa or any excipient.
- Use caution with previous hypersensitivity to factor VIII products, cardiovascular risk or a central venous access device.
Monitoring
- Monitor factor VIII activity using a validated one-stage clotting or chromogenic assay, particularly during major surgery.
- Assay reagent and reference standard can materially affect measured activity.
- Investigate for factor VIII inhibitors if expected activity is not achieved or bleeding remains uncontrolled.
- Monitor for hypersensitivity and central-line infection or thrombosis where relevant.
Clinical pharmacology
A recombinant B-domain-deleted human factor VIII covalently linked to human IgG1 Fc. It restores factor VIII cofactor activity, while FcRn-mediated recycling delays lysosomal degradation and prolongs plasma persistence.
Formulation and product differences
- Supplied as a white to off-white powder with water for injections in a pre-filled syringe; different vial strengths are available.
- The reconstituted solution is clear to slightly opalescent and colourless.
- Contains sucrose, sodium chloride, histidine, calcium chloride and polysorbate 20. Each vial is essentially sodium-free, although multiple vials may be relevant to a controlled-sodium diet.
- Use the supplied infusion set because adsorption to some injection equipment may reduce delivered factor VIII.
efmoroctocog alfa preparations and strengths
Injection
Route: Parenteral
Strengths: 250 units, 500 units, 750 units, 1000 units, 1500 units, 2000 units, 3000 units, 4000 units
efmoroctocog alfa interactions
No specific interactions with recombinant factor VIII have been reported, and formal interaction studies have not been performed. Other medicines may independently increase bleeding risk.
Aspirin and NSAIDs such as ibuprofen, naproxen or diclofenac
These can increase bleeding or bruising; check with the haemophilia team before use.
Anticoagulants such as warfarin, heparin, apixaban, rivaroxaban or dabigatran
These reduce clotting and may substantially increase bleeding risk, requiring specialist oversight.
Sources
These sources were used to prepare and review this medicine page.
Prepared and reviewed by the iatroX editorial team.